Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
|
|
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseClinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ RecruitingNot Applicable A Study Evaluating the Safety and Efficacy of hV01, a Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus, in Combination With the PD-1 Inhibitor Tislelizumab for Advanced Solid Tumors.
The purpose of this study is to evaluate the safety and primary efficacy of the combination therapy of recombinant human IL-21-expressing oncolytic vaccinia virus (hV01) and the PD-1 Inhibitor Tislelizumab in patients with advanced solid tumors.
A Phase II Trial to Evaluate the Efficacy of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Patients With Advanced Pancreatic Tumors
The main goal of this clinical trial is to preliminary evaluate the efficacy of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced pancreatic cancer.And the secondary purpose is to evaluate the safety of hV01.
重组人IL-21溶瘤痘病毒注射液(hV01)每周期单次给药治疗晚期肉瘤、宫颈癌患者的IIa期临床研究
[Translation] A Phase IIa clinical study of recombinant human IL-21 oncolytic poxvirus injection (hV01) as a single-dose treatment per cycle for patients with advanced sarcoma and cervical cancer.
主要目的:评价hV01每周期单次瘤内注射治疗晚期肉瘤、宫颈癌的初步有效性。次要目的:进一步评价hV01每周期单次瘤内注射给药的安全性。探索性目的:探索外周血免疫相关指标的改变与疗效的相关性。
[Translation] Primary objective: To evaluate the preliminary efficacy of single-cycle intratumoral injection of hV01 for the treatment of advanced sarcoma and cervical cancer. Secondary objective: To further evaluate the safety of single-cycle intratumoral injection of hV01. Exploratory objective: To explore the correlation between changes in peripheral blood immune-related markers and therapeutic efficacy.
100 Clinical Results associated with Hangzhou Converd Co., Ltd.
0 Patents (Medical) associated with Hangzhou Converd Co., Ltd.
100 Deals associated with Hangzhou Converd Co., Ltd.
100 Translational Medicine associated with Hangzhou Converd Co., Ltd.